Notably, IFN-α was approved by the FDA for the treatment of several cancers, including hairy cell leukemia, chronic myeloid leukemia, melanoma, renal cancer, myeloma, lymphomas and Kaposi's sarcoma. The gene discussed is IFNA1; the disease is cancer.